Key Points
- COO Julie Rubinstein sold 19,060 shares on April 16 at an average price of $14.18 (≈$270,271) and has carried out multiple large sales (including 141,583 shares on March 11) under a pre-arranged Rule 10b5-1 plan, reducing her ownership by 4.46% to 408,160 shares valued at about $5.79M.
- Company and market snapshot: ADPT was trading down ~3.1%, has a ~$2.17B market cap, and recently beat revenue and EPS estimates with revenue up 51% YoY but remains unprofitable; analysts hold a consensus "Moderate Buy" with a $18.25 price target (7 Buys, 1 Hold, 1 Sell).
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of the firm's stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $14.18, for a total transaction of $270,270.80. Following the completion of the transaction, the chief operating officer directly owned 408,160 shares in the company, valued at $5,787,708.80. This trade represents a 4.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Julie Rubinstein also recently made the following trade(s):
- On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.15, for a total transaction of $250,639.00.
- On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.77, for a total value of $243,396.20.
- On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.56, for a total value of $258,453.60.
- On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.83, for a total value of $458,855.03.
- On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.45, for a total value of $275,417.00.
- On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total value of $263,599.80.
- On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.37, for a total value of $254,832.20.
- On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.18, for a total value of $251,210.80.
- On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.41, for a total value of $255,594.60.
- On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07.
Adaptive Biotechnologies Trading Down 3.1%
Shares of NASDAQ ADPT opened at $14.08 on Friday. Adaptive Biotechnologies Corporation has a twelve month low of $6.77 and a twelve month high of $20.76. The stock has a 50 day moving average of $14.69 and a two-hundred day moving average of $15.98. The stock has a market cap of $2.17 billion, a P/E ratio of -35.20 and a beta of 2.29.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business's revenue was up 51.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.23) earnings per share. As a group, research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC raised its stake in Adaptive Biotechnologies by 3.1% during the 3rd quarter. Brighton Jones LLC now owns 23,301 shares of the company's stock valued at $349,000 after acquiring an additional 700 shares in the last quarter. Bouvel Investment Partners LLC lifted its position in shares of Adaptive Biotechnologies by 2.2% in the third quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company's stock worth $641,000 after buying an additional 904 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of Adaptive Biotechnologies by 1.0% in the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company's stock worth $1,145,000 after buying an additional 933 shares during the last quarter. Captrust Financial Advisors lifted its position in shares of Adaptive Biotechnologies by 7.6% in the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company's stock worth $184,000 after buying an additional 1,119 shares during the last quarter. Finally, Arizona State Retirement System lifted its position in shares of Adaptive Biotechnologies by 3.7% in the third quarter. Arizona State Retirement System now owns 31,443 shares of the company's stock worth $470,000 after buying an additional 1,120 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company's stock.
Analysts Set New Price Targets
A number of research firms recently commented on ADPT. JPMorgan Chase & Co. increased their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Friday, February 6th. Wall Street Zen downgraded Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a report on Saturday, March 7th. Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a report on Friday, February 6th. BTIG Research increased their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, February 6th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $18.25.
Get Our Latest Research Report on Adaptive Biotechnologies
Adaptive Biotechnologies Company Profile
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
